Pure Global
NCT05452902

Exercise and Nutrition Interventions for Platinum Chemotherapy-induced Neuropathy R21

The Effects of Exercise and Nutrition Interventions on Platinum Chemotherapy-induced Peripheral Neuropathy and Interoceptive Brain Circuitry (R21)
University of Maryland, Baltimore·Phase 2·ClinicalTrials.gov·behavioralNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Chemotherapy-induced Peripheral Neuropathy
Drug/Device/Intervention
EXCAP Exercise
Study type
Interventional
Intervention type
behavioral
Sponsor & location
Primary sponsor
University of Maryland, Baltimore
Location
Baltimore, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Sep 01, 2022
End date
Dec 01, 2025
Enrollment
60 participants
Primary outcome

CIPN-20 sensory subscale

Summary

Chemotherapy-induced peripheral neuropathy (CIPN) is a highly prevalent and severe
 side-effect of platinum-based chemotherapy, often used to treat gastrointestinal cancers.
 Unfortunately there are very limited treatments for CIPN. This is a phase II randomized
 controlled trial to test the preliminary efficacy of exercise vs. nutrition education on
 CIPN, to systematically investigate the potential roles of inflammation and interoception,
 and to obtain data with a more accurate effect size to inform a future study.

ICD-10 classifications
Drug-induced polyneuropathyParaneoplastic neuromyopathy and neuropathyPolyneuropathy due to other toxic agentsIdiopathic peripheral autonomic neuropathyIdiopathic progressive neuropathy
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05452902
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05452902 through Pure Global AI's free database. This Phase 2 trial is sponsored by University of Maryland, Baltimore and is currently Not yet recruiting. The study focuses on Chemotherapy-induced Peripheral Neuropathy. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.